Tylent unveils Lyvra IV automation platform in France

Tylent Technologies will introduce Lyvra™, an AI-driven IV compounding platform using magnetic levitation, at the GERPAC/ESHPT congress in Hyères, France, from Sept. 30 to Oct. 2, 2026. The launch targets French and broader European hospital pharmacies as the company tries to address low adoption of IV automation across Europe.

Why it matters: - Lyvra™ is aimed at hospital and outsourced pharmacies that need faster, more scalable IV compounding. - Tylent is pitching the platform as a response to Europe’s low adoption of IV automation, which the company puts at below 1%. - The product is designed to support pharmacy operations facing higher demand, tighter staffing and supply pressures.

What happened: - Tylent Technologies announced Lyvra™ for the French market ahead of the GERPAC/ESHPT congress in Hyères, France, on Sept. 30-Oct. 2, 2026. - The company will formally present the platform to hospital pharmacists in French and English at the event. - Tylent also plans private technology meetings during the congress. - Interested attendees can request participation by contacting arturo.caissut@tylent-technologies.com. - Press inquiries also go to arturo.caissut@tylent-technologies.com.

The details: - Lyvra™ is an automated platform for preparing IV bags. - The system combines AI-driven workflow orchestration with magnetic levitation technology developed by Beckhoff Automation. - Tylent says the platform enables parallel and multitask processing instead of sequential, single-task robotics. - The company says Lyvra™ was developed in Europe by pharmacy and mechatronics experts with decades of sector experience. - The platform is designed for safety, traceability, efficiency and scalable production from stock to patient. - Lyvra™ is built to handle controlled ISO 5 cleanroom environments. - The platform supports automated conditioning of ready-to-administer IV doses. - Tylent says the system can reduce reliance on scarce pharmacy technicians and nursing staff. - The platform is intended for hospital cleanrooms and centralized IV preparation units, including CIVAS. - A LinkedIn page for Tylent Technologies was included in the release.

Between the lines: - The launch signals a broader bet that the next phase of IV automation is not about replicating manual steps, but redesigning the whole workflow. - Tylent is positioning Lyvra™ against legacy systems that it says remain serial, slow and hard to scale in European pharmacy settings. - The focus on oncology and monoclonal antibodies suggests the platform is aimed at complex, high-volume preparation environments where bottlenecks matter most.

What's next: - Tylent will use the Hyères congress to show Lyvra™ in operation and court hospital pharmacy buyers. - The private meetings may give the company a chance to deepen technical discussions with prospective customers and partners. - The company is framing the event as an early step in broader French and European commercialization.